Zobrazeno 41 - 50
of 377
pro vyhledávání: '"Craig H. Moskowitz"'
Autor:
Julia, Driessen, Gerben J C, Zwezerijnen, Heiko, Schöder, Esther E E, Drees, Marie José, Kersten, Alison J, Moskowitz, Craig H, Moskowitz, Jakoba J, Eertink, Henrica C W de, Vet, Otto S, Hoekstra, Josée M, Zijlstra, Ronald, Boellaard
Publikováno v:
J Nucl Med
Consensus about a standard segmentation method to derive metabolic tumor volume (MTV) in classical Hodgkin lymphoma (cHL) is lacking, and it is unknown how different segmentation methods influence quantitative PET features. Therefore, we aimed to eva
Autor:
Ahmet Dogan, Heiko Schöder, Oscar B Lahoud, Santosha Vardhana, Theresa Davey, Craig H. Moskowitz, Anita Kumar, M. Lia Palomba, Brielle Liotta, Paul A. Hamlin, Beatriz Wills Sanin, Colette Owens, William T. Johnson, Joachim Yahalom, Matthew J. Matasar, Connie Lee Batlevi, Christina R. Lee, Alayna Santarosa, Helen Hancock, Lorenzo Falchi, Esther Drill, Audrey Hamilton, Alison J. Moskowitz, Samia Sohail, Rachel Neuman, Gunjan L. Shah, Sunyoung Ryu, Natasha Galasso, David J. Straus, Gilles Salles, Georgios Pongas, William Blouin, Steven M. Horwitz, Ariela Noy, Erel Joffe, Ildefonso Rodriguez-Rivera, Andrew D. Zelenetz, Andrew M. Intlekofer, Gottfried von Keudell, Nivetha Ganesan, Philip Caron, Leslie Perez
Publikováno v:
J Clin Oncol
PURPOSE We conducted a phase II study evaluating pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) as second-line therapy for relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) (ClinicalTrials.gov iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9666753bc8fb50bed83326e0a6db7606
https://europepmc.org/articles/PMC9851707/
https://europepmc.org/articles/PMC9851707/
Autor:
Heiko Schöder, A.J. Moskowitz, Julia Driessen, Jakoba J Eertink, Ronald Boellaard, G.J.C. Zwezerijnen, Tim van de Brug, H. C. W Vet, Craig H. Moskowitz, Otto S. Hoekstra, Marie-Jose Kersten, J. M. Zijlstra
Publikováno v:
Hematological Oncology. 39
Autor:
Erel Joffe, Colette Owens, Craig H. Moskowitz, Audrey Hamilton, Steven M. Horwitz, Ariela Noy, Alison J. Moskowitz, Matthew J. Matasar, Ildefonso Rodriguez-Rivera, Edith Tama Robin, Andrew D. Zelenetz, David J. Straus, Connie Lee Batlevi, Anita Kumar, Maria Lia Palomba, Philip Caron, Esther Drill, Lorenzo Falchi, Paul A. Hamlin, Santosha Vardhana, Gottfried von Keudell, Andrew M. Intlekofer
Publikováno v:
Blood. 136:36-38
Background T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is an uncommon variant of diffuse large B cell lymphoma (DLBCL), characterized by low content of lymphoma cells in a background of extensive infiltrate of T-cells and histiocytes. Hist
Autor:
Joachim Yahalom, Karen Chau, Carol S. Portlock, Andrew D. Zelenetz, Ahmet Dogan, A.J. Xu, David J. Straus, Morton Coleman, Monica Chelius, Carla Hajj, Ariela Noy, Stephanie Lobaugh, Zhigang Zhang, Craig H. Moskowitz, Brandon S. Imber
Publikováno v:
Blood Adv
Treatment options for Helicobacter pylori–independent gastric mucosa-associated lymphoid tissue (MALT) lymphoma (GML) include surgery, immunotherapy, chemotherapy, and radiation therapy (RT). The purpose of this study was to investigate the efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::299207837cf8340351dd017e0e6c6b46
https://europepmc.org/articles/PMC8045489/
https://europepmc.org/articles/PMC8045489/
Autor:
Colette Owens, Augustine Iannotta, Paul A. Hamlin, Gilles Salles, Beatriz Korc-Grodzicki, Matthew J. Matasar, Mayan Oliveros, Ariela Noy, Dylan L Schick, Craig H. Moskowitz, Pamela Drullinsky, Philip Caron, John F. Gerecitano, Esther Drill, Andrew D. Zelenetz, Anita Kumar, Richard J. Lin
Publikováno v:
Haematologica. 107(5)
Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as func
Autor:
Andrew M. Evens, Paul M. Barr, Ann S. LaCasce, Sonali M. Smith, Michael V. Knopp, John P. Leonard, Deborah M. Stephens, David J. Straus, Hongli Li, Michael LeBlanc, Lisa M. Rimsza, Craig H. Moskowitz, Brad S. Kahl, Jonathan W. Friedberg, Heiko Schöder, Eric D. Hsi, Nancy L. Bartlett
Publikováno v:
J Nucl Med
Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on S0816 (NCT00822120). Patients received 2 cycles of doxorubicin, ble
Publikováno v:
Expert Review of Hematology. 12:407-418
Introduction: Molecular and biologic heterogeneity in diffuse large B-cell lymphoma (DLBCL) has resulted in a broad range of clinical outcomes. While standard frontline chemoimmunotherapy cures majority of patients with DLBCL, treatment failure in ce
Autor:
Craig H. Moskowitz
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S197-S198
Classical Hodgkin lymphoma (HL) is often cured with frontline therapy; however, up to 15–25% patients with advanced stage and up to 10% with early stage need additional treatment. When second-line therapy is required, up to 2/3 of patients are cure
Autor:
Andy I. Chen, Veronika Bachanova, Julie Lisano, Tamás Masszi, Jerzy Holowiecki, Auayporn Nademanee, Patrick J. Stiff, Craig H. Moskowitz, Simonetta Viviani, Connie Lee, Teresa McClendon, Muneer H. Abidi, Anna Sureda, Jan Walewski, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 132:2639-2642
The phase 3 AETHERA trial established brentuximab vedotin (BV) as a consolidative treatment option for adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression after autologous hematopoietic stem-cell transplantatio